3,826 reports of this reaction
1.4% of all ADALIMUMAB FKJP reports
#13 most reported adverse reaction
JOINT SWELLING is the #13 most commonly reported adverse reaction for ADALIMUMAB FKJP, manufactured by Biocon Biologics Inc. There are 3,826 FDA adverse event reports linking ADALIMUMAB FKJP to JOINT SWELLING. This represents approximately 1.4% of all 281,217 adverse event reports for this drug.
Patients taking ADALIMUMAB FKJP who experience joint swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
JOINT SWELLING is a less commonly reported adverse event for ADALIMUMAB FKJP, but still significant enough to appear in the safety profile.
In addition to joint swelling, the following adverse reactions have been reported for ADALIMUMAB FKJP:
The following drugs have also been linked to joint swelling in FDA adverse event reports:
JOINT SWELLING has been reported as an adverse event in 3,826 FDA reports for ADALIMUMAB FKJP. This does not prove causation, but indicates an association observed in post-market surveillance data.
JOINT SWELLING accounts for approximately 1.4% of all adverse event reports for ADALIMUMAB FKJP, making it a notable side effect.
If you experience joint swelling while taking ADALIMUMAB FKJP, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.